UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a ...

Neupro (rotigotine transdermal system, from UCB and Schwarz Pharma) patches are being recalled due to the formation of rotigotine crystals in the patches. When the drug crystallizes, less drug is ...

UCB has announced the launch of Neupro in the United States for the treatment of Parkinson’s disease and restless legs syndrome. The once-daily patch provides continuous delivery of the dopamine ...

April 12 (Reuters) - Belgian biopharmaceutical company UCB (UCB.BR), opens new tab on Wednesday lost its U.S. court appeal seeking to revive a patent covering its Parkinson's disease drug Neupro ...